Recombinant
RabMAb

Recombinant Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)

Submit a review Submit a question

Overview

  • Product name

    Anti-VEGF Receptor 2 antibody [EPR21884-236]
    See all VEGF Receptor 2 primary antibodies

  • Description

    Rabbit monoclonal [EPR21884-236] to VEGF Receptor 2

  • Host species

    Rabbit

  • Tested applications

    Suitable for: Flow Cyt, ICC/IFmore details

  • Species reactivity

    Reacts with: Mouse

  • Immunogen

    Recombinant fragment within Mouse VEGF Receptor 2 aa 1-800. The exact sequence is proprietary.
    Database link: P35918

  • Positive control

    • ICC/IF: bEnd.3 cells. Flow Cyt: bEnd.3 cells.

  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Applications

Our Abpromise guarantee covers the use of ab233693 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt 1/500.
ICC/IF 1/1000.

Target

  • Function

    Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.

  • Involvement in disease

    Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.

  • Sequence similarities

    Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
    Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.

  • Post-translational
    modifications

    Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.

  • Cellular localization

    Membrane.
  • Information by UniProt

  • Database links

    • Alternative names

      • CD309 antibody
      • CD309 antigen antibody
      • EC 2.7.10.1 antibody
      • Fetal liver kinase 1 antibody
      • FLK-1 antibody
      • FLK1 antibody
      • FLK1, mouse, homolog of antibody
      • Kdr antibody
      • Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody
      • Kinase insert domain receptor antibody
      • KRD1 antibody
      • Ly73 antibody
      • Protein tyrosine kinase receptor FLK1 antibody
      • Protein-tyrosine kinase receptor flk-1 antibody
      • soluble VEGFR2 antibody
      • Tyrosine kinase growth factor receptor antibody
      • Vascular endothelial growth factor receptor 2 antibody
      • VEGFR 2 antibody
      • VEGFR antibody
      • VEGFR-2 antibody
      • VEGFR2 antibody
      • VGFR2_HUMAN antibody
      see all

    Images

    • Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)
      Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)

      Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized bEnd.3 (mouse brain endothelioma cell line) and NIH/3T3 (mouse embryo fibroblast cell line) cells labeling VEGF Receptor 2 with ab233693 at 1/1000 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing perinuclear staining in bEnd.3 cells.

      Negative control: NIH/3T3  [PMID: 20978347].

      The nuclear counter stain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) (red) at 1/200 dilution.

      Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution.

    • Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)
      Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)

      Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized bEnd.3 (mouse brain endothelioma) cells labeling VEGF Receptor 2 with ab233693 at 1/1000 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Redistribution of the VEGF Receptor 2 from the perinuclear Golgi to vesicular structures throughout the cytosol after treatment with Brefeldin A (1 μg/ml, 3 hours) in bEnd.3. BFA treatment alters the subcellular localisation of VEGF Receptor 2 [PMID: 21063020].

      The nuclear counter stain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) (red) at 1/200 dilution.

      Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution.

    • Flow Cytometry - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)
      Flow Cytometry - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)

      Flow cytometric analysis of bEnd.3 (mouse brain endothelioma cell line, right) and NIH/3T3 (mouse embryo fibroblast cell line, left) cell line labeling VEGF Receptor 2 with ab233693 at 1/500 dilution compared with a Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) at 1/2000 dilution was used as the secondary antibody.

      Gated on viable cells.

      Negative control: NIH/3T3 [PMID: 20978347].

    • Flow Cytometry - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)
      Flow Cytometry - Anti-VEGF Receptor 2 antibody [EPR21884-236] (ab233693)

      Flow cytometric analysis of bEnd.3 (mouse brain endothelioma cell line) cell line treated with 1 μg/ml Brefeldin A for 3 hours (red) and an untreated control (green) labeling VEGF Receptor 2 with ab233693 at 1/500 dilution treated with a Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) at 1/2000 dilution was used as the secondary antibody.

      BFA treatment reduced cell surface VEGF Receptor 2 [PMID: 21063020].

      Gated on viable cells.

    References

    ab233693 has not yet been referenced specifically in any publications.

    Publishing research using ab233693? Please let us know so that we can cite the reference in this datasheet.

    Customer reviews and Q&As

    Show All Reviews Q&A
    Submit a review Submit a question

    There are currently no Customer reviews or Questions for ab233693.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up